TNP 2092

Drug Profile

TNP 2092

Alternative Names: CBR-2092; TNP-2092; TNP-2092 IV; TNP-2092 PO

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cumbre Pharmaceuticals
  • Developer TenNor Therapeutics
  • Class Antibacterials; Quinolizines; Rifamycins
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA topoisomerase IV inhibitors; DNA-directed RNA polymerase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 23 Aug 2018 Phase-I clinical trials in Bacterial infections in China (PO), before August 2018 (TenNor pipeline, August 2018)
  • 23 Aug 2018 TenNor Therapeutics plans a phase III trial for Implant infections
  • 02 Aug 2018 Phase-II clinical trials in Bacterial infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top